Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MEDVidi vs Vea Health

MEDVidi
Graded #384

Higher grade

vs+3
Vea Health
Graded #450

Lower grade

The verdict

MEDVidi takes it — 58/100 to 55/100.

MEDVidi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide), plus…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationMEDVidi +2
53
51
Clinical oversightMEDVidi +11
77
66
Labs & monitoringMEDVidi +10
62
52
FulfillmentVea Health +9
59
68
Contract termsEven
55
55
MEDVidi · left barVea Health · right bar

The numbers

MetricMEDVidiVea Health
WeighScore58/10055/100
GradeCC
Scorecard rank#384#450
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
MEDVidi

Graded #384 · C

Strengths

  • Licensed providers can prescribe brand-name Zepbound and Wegovy
  • Transparent flat consultation fees (195 dollar initial, 159 dollar follow-up)
  • Prescriptions sent to the patient's pharmacy of choice, so insurance can be used

Where it loses points

  • Consult-fee model: medication is not included and its cost is separate
  • No medication pricing is published
  • State list is shown as a map rather than enumerated
Vea Health

Graded #450 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard